Amanta Healthcare Ltd IPO 2025: Date, Price Band, GMP, Financials & Review

Introduction

Amanta Healthcare Ltd, an Ahmedabad-based pharma firm, is stepping into the spotlight. Specializing in sterile liquid products and medical devices, the company’s upcoming IPO promises to turn heads. This blog dives into everything you need to know—in fresh, original language.

🏢Company Overview

Founded in 1994, Amanta Healthcare develops, manufactures, and markets sterile liquid products using advanced technologies Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). Their product range includes large and small volume parenterals (LVPs and SVPs), IV fluids, ophthalmic and respiratory solutions, irrigation products, and even medical devices like eye lubricants and first-aid kits.

With over 45 generic formulations marketed under its own brands, Amanta’s reach extends through a network of more than 320 distributors across India. The company also exports to 21 countries, including Africa, Latin America, and the UK.

📊 IPO Details

Allocation Breakup:

• QIBs: up to 50%
• NIIs: at least 15%
• Retail: at least 35%

📌Objectives of the IPO

Funds raised will be used for:

• Setting up a new SteriPort manufacturing line at Hariyala, Kheda, Gujarat (~₹70 crore)
• Building a new SVP (small volume parenterals) line at the same facility (~₹30.13 crore)
• General corporate purposes

💰Financial Performance

Additional metrics for FY25:

• ROE: 12.4%
• ROCE: 13.7%
• Debt/Equity: 2.02×, PAT Margin: 3.86%, EBITDA Margin: 22.1%

📈 Strengths & Risks

Strengths :

• Advanced manufacturing (ABFS & ISBM) creating product moves from 2 ml–1000 ml .
• Wide distribution and export reach, with 320+ domestic distributors and business across 21 countries
• Strong financial turnaround and growing profitability

Risks :

• Modest margins and moderate leverage (Debt/Equity ~2×)
• Valuation (P/E ~46.6 at ₹126 price) above pharma average (~35×), but lower than top-tier companies like Sun Pharma (~72×)
• QIB subscription was low in initial phase—could indicate cautious institutional interest

📈 Grey Market Premium (GMP)

Grey market indicators hint at strong listing potential:

• GMP ranged between ₹22 to ₹29, implying ~17–23% premium over ₹126 upper band
• By Day 2, GMP stabilized at ~12%, while subscription soared to 12.4×

** Disclaimer:** GMP is unofficial and should not be the sole investment guide.

📈Subscription Status

• Day 1: Subscription ranged from 4.55× to 4.61× across sources, led by retail (6.6×–6.7×), NIIs (≈5.8×), while QIBs lagged (≈0.04×)
• Day 2: Overall subscription jumped to 12.4×, signaling strong investor demand

📌Should You Apply?

If you’re looking for short-term listing gains, the pricing and GMP suggest a potentially rewarding debut. For long-term investors, beware of high valuations and moderate margins. Carefully weigh fundamentals and your own risk appetite. As always, this is educational only—not financial advice.

📌How to Apply

1. Through Demat Account (ASBA): Apply via your bank’s IPO section or broker’s platform.
2. Choose Price Band: Select ₹120–126.
3. Send Mandate: Use UPI or net banking (deadline ~5 PM on Sept 3)
4. Track Allotment: Expect around Sept 4.
5. Shares Credit & Listing: Shares credited by Sept 8 and likely listed by Sept 9.

📌Conclusion

Amanta Healthcare’s IPO is shaping up as a high-demand issue—with robust GMP trends, strong subscription, and sound growth plans. Balanced perspective is vital. Monitor the listing dynamics and fundamentals closely.

⚠️ Disclaimer

This article is for educational purposes only and must not be construed as financial advice. Please consult your financial advisor before taking any investment decisions.

Internal Link :-

• Rachit Prints Ltd IPO 2025: Price Band, Dates, Financials & Review
• Abril Paper Tech IPO 2025: Price, GMP, Lot Size, Dates, Financials & Key Detail
• Sugs Lloyd IPO 2025 – Dates, Price Band, GMP, Allotment & Review
• Snehaa Organics IPO 2025 – Price Band, GMP, Subscription, Allotment & Detailed Review

External Link :-

• Amanta Healthcare
• NSE
• BSE
• SEBI